A Phase 2 Multicenter Open-Label Study Evaluating the Efficacy and Safety of TYRA-300 in Participants with FGFR3 Altered Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer

Go Back to All Clinical Trials

A Phase 2 Multicenter Open-Label Study Evaluating the Efficacy and Safety of TYRA-300 in Participants with FGFR3 Altered Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer

Brief description of study

This study will investigate the safety, tolerability of TYRA-300 and assess different doses of TYRA-300 in participants harboring FGFR3 mutations and/or fusions with intermediate risk NMIBC in order to identify the Phase 3 dose. Utilizing a Simons 2-Stage Design, a dosing cohort will be evaluated after approximately 15 participants have been enrolled with an expansion to 30 participants.

Clinical Study Identifier: s25-01269

ClinicalTrials.gov Identifier: NCT06995677

Principal Investigator: Katie S. Murray.

Other Investigators: Caitlin Elizabeth Ordonez Ferri, Tiffany M Tomberlin, James S Wysock, Anam Qureshi, Victor Ricardo Adorno Febles, Kenia J Rodriguez, Carol M Lee, Laura Catherine Bauer, Doris M Salazar, Jonathan B Kahn, Minas Platon Economides, William C Huang, Jiping Zeng, Wei Phin Tan, David R. Wise.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies